Predictive action of oncomiR in suppressing TP53 signaling pathway in hypoxia‐conditioned colon cancer cell line HCT‐116
Cell Biology International · 2024
DOI: 10.1002/cbin.12243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, 2024. Verfasst von R Susanti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Mathematics and Natural Science, Universitas Negeri Semarang, Semarang, Indonesia. Hauptthemen laut MEDLINE: MicroRNAs, Signal Transduction, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Directorate General of Higher Education, Research and Technology, Ministry of Education, Culture, Research and Technology of the Republic of Indonesia.
Abstract (Originalsprache)
Hypoxia‐induced heterogeneity in colorectal cancer (CRC) significantly impacts patient survival by promoting chemoresistance. These conditions alter the regulation of miRNAs, key regulators of crucial processes like proliferation, apoptosis, and invasion, leading to tumor progression. Despite their promising potential as diagnostic and therapeutic targets, the underlying mechanisms by which miRNAs influence hypoxia‐mediated tumorigenesis remain largely unexplored. This study aims to elucidate the action of miRNAs in HCT‐116 colorectal cancer stem cells (CSCs) under hypoxia, providing valuable insights into their role in tumor adaptation and progression. MiRNA expression was determined using Nanostring nCounter, and bioinformatic analysis was performed to explain the molecular pathway. A total of 50 miRNAs were obtained with an average count of ≥ 20 reads for comparative expression analysis. The results showed that hypoxia‐affected 36 oncomiRs were increased in HCT‐116, and 14 suppressor‐miRs were increased in MSCs. The increase in miRNA expression occurred consistently from normoxia to hypoxia and significantly differed between mesenchymal stem cells (MSCs) and HCT‐116. Furthermore, miR‐16‐5p and miR‐29a‐3p were dominant in regulating the p53 signaling pathway, which is thought to be related to the escape mechanism against hypoxia and maintaining cell proliferation. More research with a genome‐transcriptome axis approach is needed to fully understand miRNAs’ role in adapting CRC cells and MSCs to hypoxia. Further research could focus on developing specific biomarkers for diagnosis. In addition, anti‐miR can be developed as a therapy to prevent cancer proliferation or inhibit the adaptation of cancer cells to hypoxia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Mathematics and Natural Science, Universitas Negeri Semarang, Semarang, Indonesia.
- Doctoral Program of Biotechnology, Postgraduate School, Universitas Gadjah Mada, Yogyakarta, Indonesia.
- Department of Biomedical Science, Faculty of Medicine, Universitas Islam Sultan Agung, Semarang, Indonesia.
- Stem Cell and Cancer Research (SCCR), Faculty of Medicine, Universitas Islam Sultan Agung, Semarang, Indonesia.
ORCID-Profile: Muchamad Dafip, Dewi Mustikaningtyas, Agung Putra
Förderung
- Directorate General of Higher Education, Research and Technology, Ministry of Education, Culture, Research and Technology of the Republic of Indonesia
Zitieren
APA
Susanti, R., Dafip, M., Mustikaningtyas, D., & Putra, A. (2024). Predictive action of oncomiR in suppressing TP53 signaling pathway in hypoxia‐conditioned colon cancer cell line HCT‐116. Cell Biology International. https://doi.org/10.1002/cbin.12243
Vancouver
Susanti R, Dafip M, Mustikaningtyas D, Putra A. Predictive action of oncomiR in suppressing TP53 signaling pathway in hypoxia‐conditioned colon cancer cell line HCT‐116. Cell Biology International. 2024. doi:10.1002/cbin.12243
BibTeX
@article{Susanti2024,
author = {Susanti, R and Dafip, Muchamad and Mustikaningtyas, Dewi and Putra, Agung},
title = {Predictive action of oncomiR in suppressing TP53 signaling pathway in hypoxia‐conditioned colon cancer cell line HCT‐116},
journal = {Cell Biology International},
year = {2024},
doi = {10.1002/cbin.12243}
}
EUVIMED